MedTrace Logo

Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program

NCT01009567 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-05-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of cabergoline in prevention of ovarian hyperstimulation syndrome versus albumin in ART program.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Cabergoline

Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval

DRUG

Control

Receive human albumin 20% infusion

Sponsors & Collaborators

  • Royan Institute

    lead OTHER_GOV

Principal Investigators

  • Eniseh Tehraninejad, MD · Royan Institute

  • Ashraf Moini, MD · Board scientific

  • Marzieh Shiva, MD · scientist

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-06-30
Completion
2013-07-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009567 on ClinicalTrials.gov